Guideline on safer conception in fertile HIV-infected individuals and couples

Southern African Journal of HIV Medicine

Volumn , Issue 40, 2011, Pages 31-44

  Bekker, L G ^a   Black, V ^a   Myer, L ^a   Rees, H ^a   Cooper, D ^a   Mall, S ^a   Mnyami, C ^a   Conradie, F ^a   Mahabeer, I ^a   Gilbert, L ^a   Schwartz, S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; COPPER INTRAUTERINE DEVICE; EFAVIRENZ; EMTRICITABINE; GESTAGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LEVONORGESTREL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; RIFAMPICIN; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTIFICIAL INSEMINATION; BASAL BODY TEMPERATURE; BREAST FEEDING; CASE REPORT; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; COMORBIDITY; CONCEPTION; CONDOM; DRUG SAFETY; DRUG SUBSTITUTION; FAMILY PLANNING; FEMALE; FEMALE FERTILITY; FEMALE STERILIZATION; FERTILIZATION IN VITRO; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAVENOUS DRUG ABUSE; MALE FERTILITY; MALE STERILIZATION; MARITAL THERAPY; MEDICAL DOCUMENTATION; MENSTRUAL CYCLE; NAUSEA; OVARY CYCLE; OVULATION DETECTION; PAPANICOLAOU TEST; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; POST EXPOSURE PROPHYLAXIS; PRACTICE GUIDELINE; PRE EXPOSURE PROPHYLAXIS; PREGNANCY; PRENATAL CARE; REVIEW; SALIVA ANALYSIS; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; TERATOGENICITY; TUBERCULOSIS; URINALYSIS; UTERINE CERVIX MUCUS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING;

EID: 79960015694     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: 10.4102/sajhivmed.v12i2.196     Document Type: Review

References (32)

1. Mofenson LM. Protecting the next generation - eliminating perinatal HIV-1 infection. N Engl J Med 2010;362(24):2316-2318.
2. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, Abrams EJ. Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa. a cohort study PLoS Med 2010;7(2).e1000229.
3. Gruskin S, Ferguson L, O'Malley J. Ensuring sexual and reproductive health for people living with HIV: an overview of key human rights, policy and health systems issues. Reprod Health Matters 2007;15(29 Suppl):4-26. (Pubitemid 46771203)
4. Dyer SJ. The value of children in African countries: insights from studies on infertility. J Psychosom Obstet Gynaecol 2007;28(2):69-77. (Pubitemid 46854806)
5. Cooper D, Moodley J, Zweigenthal V, Bekker LG, Shah I, Myer L. Fertility intentions and reproductive health care needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav 2009,13 Suppl 1:38-46.
6. Cooper D, Harries J, Myer L, Orner P, Bracken H, Zweigenthal V. 'Life is still going on': reproductive intentions among HIV-positive women and men in South Africa. Soc Sci Med 2007;65(2):274-283.
7. Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa AIDS Patient Care STDS 2007;21(4):278-285.
8. Kaida A, Laher F, Strathdee SA, Money D, Janssen PA, Hogg RS, Gray G. Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. PLoS One 2010;5(11):e13868.
9. Heikinheimo O, Lähteenmäki P. Contraception and HIV infection in women. Hum Reprod Update 2009;15(2):165-176.
10. World Health Organization. Medical Eligibility for Criteria for Contraceptive Use, 2008 Update. WHO/RHR/08.19. Geneva: WHO, 2008.
11. Trussell J. Contraceptive efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, eds. Contraceptive Technology. 19th rev ed. New York: Ardent Media, 2007.
12. Granich R, Crowley S, Vitoria M, Smyth C, Kahn JG, Bennett R, Lo YR, Souteyrand Y, Williams B. Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Curr Opin HIV AIDS 2010;5(4):298-304.
13. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-927.
14. Liuzzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996;10:51-56.
15. Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000;14(4):415-421. (Pubitemid 30182438)
16. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000;14(2):117-121. (Pubitemid 30116436)
17. Initiation of Antiretroviral Treatment Protects Uninfected Sexual Partners from HIV Infection (HPTN Study 052). http://www.hptn.org/ web%20documents/PressReleases/HPTN052PressReleaseFINAL5-12-118am.pdf
18. Coombs RW, Speck CE, Hughes JP, et al. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998;177:320-330. (Pubitemid 28063755)
19. Gilling-Smith C, Nicopoullos JDM, Cox A, Almeida P, Wood R, Vourliotis M. Detectable HIV in semen from HIV-positive men on HAART with undetectable serum viral load. Human reproduction. Presented at the European Society for Human Reproduction and Embryology (ESHRE) 24th Annual Meeting, Barcelona, 6-9 July 2008.
20. Frodsham LCG, Cox AD, Almeida A, Rozis G, Gilling-Smith C. In vitro fertilisation in HIV-positive women: potential mother-to-embryo viral transmission risk. Hum Reprod 2004;9:138.
21. Minkoff H, Santoro N Ethical considerations in the treatment of infertility in women with human immunodeficiency virus infection. N Engl J Med 2000;342:1748-1750. (Pubitemid 30354526)
22. Barreiro P, del Romero J, Leal M, et al. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:324-326. (Pubitemid 44674013)
23. Vernazza P. HAART improves quality of life: should we care about the quality of spermatozoa? AIDS 2008;22:647-648.
24. Fitzgerald FC, Bekker LG, Kaplan R, Myer L, Lawn SD, Wood R. Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa. S Afr Med J 2010;100(12):827-831.
25. Efavirenz-based regimens among women of reproductive age receiving ART in Johannesburg. http://i-base.info/htb/13998
26. Piantadosi A, Chohan B, Chohan V, McClelland RS, Overbaugh J. Chronic HIV-1 infection. Frequently fails to protect against superinfection. PLoS Pathog 2007;3(11):e177. doi:10.1371/journal.ppat.0030177.
27. Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH; Praca Onze Study Team. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV J Acquir Immune Defic Syndr 2004;35(5):519-525.
28. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010;2(14):14ra4.
29. Lunding S, Katzenstein TL, Kronborg G, Lindberg JA, Jensen J, Nielsen HI, Pedersen C, Jørgensen LB The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis 2010;37(1):49-52.
30. Grant RM, Lama JR, Anderson PL; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363(27):2587-2599 Epub 2010 Nov 23.
31. FHI to Initiate Orderly Closure of FEM-PrEP. http://www.fhi.org/en/ AboutFHI/Media/Releases/FEM-PrEP-statement041811.htm
32. AVAC: Ongoing PREP trials as of Feb 2011. http://www.avac.org/ht/a/ GetDocumentAction/i/3113